Pazopanib US FDA Label
- Compound: 5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
- Description: Pazopanib is a pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor, a vascular endothelial growth factor receptor antagonist and an angiogenesis modulating agent. It is a member of indazoles, an aminopyrimidine and a sulfonamide. It is a conjugate base of a pazopanib(1+).
- Brand Name:
- Code(s): GW786034
- Approved:
- Kinase Class: RY
- Inhibitor Type: ?
- Literature (PubMed): 0
- Target(s): Colony stimulating factor 1 receptor , fibroblast growth factor receptor 1 , fibroblast growth factor receptor 3 , Fms related receptor tyrosine kinase 1 , fms related receptor tyrosine kinase 4 , IL2 inducible T cell kinase , kinase insert domain receptor , KIT proto-oncogene, receptor tyrosine kinase , LCK proto-oncogene, Src family tyrosine kinase , Platelet derived growth factor receptor alpha , Platelet derived growth factor receptor beta
- Disease(s): renal cell carcinoma , soft-tissue sarcoma